Trial Profile
A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; Decitabine (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 27 Jun 2013 Eisai added as trial company and lead trial centre as reported by ClinicalTrials.gov.
- 27 Jun 2013 Eisai added as trial company and lead trial centre as reported by ClinicalTrials.gov.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.